| 产品名称 | PX 20350 - FXR agonist Cpd 22 |
| 产品货号 | Axon 2152 CAS [1198085-23-2] MF C28H22Cl2F3N3O4MW 592.39 Purity: 99% Soluble in DMSO Description Potent farnesoid X receptor (FXR) agonist with enhanced affinity and efficacy (12 nM and 109% (compared to GW 4064)) in FXR FRET assay and full length FXR direct reporter (DR) assay (6 nM vs 30 nM for GW 4064). Cpd 22 showed a linear dose-dependent reduction in total plasma triglycerides and total plasma cholesterol. References Certificates Categories Extra info U. Abel et al. Synthesis and pharmacological validation of a novel series of non-steroidal FXR agonists. Bioorg. Med. Chem. Lett. 2010, 20, 4911–4917. U. Deuschle et al. FXR controls the tumor suppressor NDRG2 and FXR agonists reduce liver tumor growth and metastasis in an orthotopic mouse xenograft model. PLoS One. 2012, 7, e43044. Certificate of Analysis Material Safety Data Sheet Cell Signaling & Oncology FXR NR1H Potent farnesoid X receptor (FXR) agonist Chemical name 4-(((6-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)-2-(trifluoromethyl)pyridin-3-yl)(methyl)amino)methyl)benzoic acid Parent CAS No. [1198085-23-2] Order Size Unit Price Stock 5 mg €105.00 In Stock |
| 产品价格 | 现货询价，电话：010-67529703 |
| 产品规格 | |
| 产品品牌 | axonmedchem |
| 产品概述 | |
| 产品详情 |
PX 20350 - FXR agonist Cpd 22Axon 2152 CAS [1198085-23-2] MF C28H22Cl2F3N3O4
Description
Potent farnesoid X receptor (FXR) agonist with enhanced affinity and efficacy (12 nM and 109% (compared to GW 4064)) in FXR FRET assay and full length FXR direct reporter (DR) assay (6 nM vs 30 nM for GW 4064). Cpd 22 showed a linear dose-dependent reduction in total plasma triglycerides and total plasma cholesterol.
Potent farnesoid X receptor (FXR) agonist
Chemical name4-(((6-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)-2-(trifluoromethyl)pyridin-3-yl)(methyl)amino)methyl)benzoic acid Parent CAS No.[1198085-23-2] |
| 产品资料 |
